Imidazopyrazine inhibitors of Bruton's tyrosine kinase

Patent metadata

Field	Value
Publication number	US-10736893-B2
Application number	US-201615773846-A
Country	US
Kind code	B2
Filing date	Nov 4, 2016
Priority date	Nov 6, 2015
Publication date	Aug 11, 2020
Grant date	Aug 11, 2020

Abstract

In some embodiments, the invention relates to a BTK inhibitor or a pharmaceutically acceptable salt, cocrystal, ester, prodrug, solvate, hydrate or derivative thereof, or to pharmaceutical compositions comprising these compounds and to their use in therapy. In particular, in some embodiments, the present invention relates to imidazopyrazine compounds, pharmaceutical compositions thereof, and the use of the compounds and pharmaceutical compositions in the treatment of a hyperproliferative disorder, an inflammatory disorder, an immune disorder, or an autoimmune disorder.

First claim

We claim:

1. A compound of Formula (I) having the structure:

or a pharmaceutically acceptable salt thereof, wherein:
R 1 is hydrogen or methoxy, wherein methoxy is optionally substituted with one or two fluoro;
X is:

Y is:

R 3 is H or methyl.

2. A pharmaceutical composition comprising a compound of claim 1 and at least one pharmaceutically acceptable excipient.

Assignees

• Acerta Pharma Bv

Inventors

• Barf Tjeerd
• De Zwart Edwin
• Verkaik Saskia
• Hoogenboom Niels
• Demont Dennis

Classifications

• C07D487/04

  Ortho-condensed systems · CPC title

• A61P29/00

  Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID] · CPC title

• A61K31/4985 Primary

  Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems · CPC title

• A61P35/04

  specific for metastasis · CPC title

• A61P35/02

  specific for leukemia · CPC title